Sep 3, 2019 · With placebo, the incidence of death by respective vascular categories was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with alirocumab ...
The aims of this pre-specified analysis of the ODYSSEY OUTCOMES trial were to determine whether the benefits of alirocumab on MACE and death were influenced by ...
Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease death, ...
(Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During ... the ODYSSEY OUTCOMES trial. Am Heart J 2014;. 168:682–9. 14. Schwartz GG ...
BACKGROUND: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events ...
The ODYSSEY OUTCOMES trial compared alirocumab with placebo, beginning 1 to 12 months after ACS with median 2.8-year follow-up. The primary MACE outcome ...
People also ask
How effective is Evolocumab on cardiovascular outcomes in patients with recent myocardial infarction?
What is the effect of alirocumab on stroke in Odyssey outcomes?
What are the new antithrombotic drugs in acute coronary syndrome?
What are the different types of acute coronary syndrome?
Vascular reactivity to mental stress is associated with poor cardiovascular disease outcomes in females following acute coronary syndrome. · Risk Factors for ...
May 16, 2023 · The ODYSSEY OUTCOMES trial showed that use of alirocumab, taken every other week, significantly reduces ischemic events, including all-cause mortality and MI.
Missing: Polyvascular | Show results with:Polyvascular
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial. / Jukema, J.W.; Szarek, M.; Zijlstra, L.E. et al.
Data from the large ODYSSEY OUTCOMES trial in over 18,000 patients after an ACS showed significant reductions in major cardiovascular events in several risk ...